TY - JOUR
T1 - Tetrahedral spectral feature-Based bayesian manifold learning for grey matter morphometry
T2 - Findings from the Alzheimer's disease neuroimaging initiative
AU - Fan, Yonghui
AU - Wang, Gang
AU - Dong, Qunxi
AU - Liu, Yuxiang
AU - Leporé, Natasha
AU - Wang, Yalin
N1 - Funding Information:
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
This work was partially supported by National Institutes of Health (RF1AG051710, R01EB025032 and R21AG065942), the Arizona Alzheimer's Consortium, and Natural Science Foundation of China (61772253). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co. Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
This work was partially supported by National Institutes of Health (RF1AG051710, R01EB025032 and R21AG065942), the Arizona Alzheimer’s Consortium, and Natural Science Foundation of China (61772253).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8
Y1 - 2021/8
N2 - Structural and anatomical analyses of magnetic resonance imaging (MRI) data often require a reconstruction of the three-dimensional anatomy to a statistical shape model. Our prior work demonstrated the usefulness of tetrahedral spectral features for grey matter morphometry. However, most of the current methods provide a large number of descriptive shape features, but lack an unsupervised scheme to automatically extract a concise set of features with clear biological interpretations and that also carries strong statistical power. Here we introduce a new tetrahedral spectral feature-based Bayesian manifold learning framework for effective statistical analysis of grey matter morphology. We start by solving the technical issue of generating tetrahedral meshes which preserve the details of the grey matter geometry. We then derive explicit weak-form tetrahedral discretizations of the Hamiltonian operator (HO) and the Laplace-Beltrami operator (LBO). Next, the Schrödinger's equation is solved for constructing the scale-invariant wave kernel signature (SIWKS) as the shape descriptor. By solving the heat equation and utilizing the SIWKS, we design a morphometric Gaussian process (M-GP) regression framework and an active learning strategy to select landmarks as concrete shape descriptors. We evaluate the proposed system on publicly available data from the Alzheimers Disease Neuroimaging Initiative (ADNI), using subjects structural MRI covering the range from cognitively unimpaired (CU) to full blown Alzheimer's disease (AD). Our analyses suggest that the SIWKS and M-GP compare favorably with seven other baseline algorithms to obtain grey matter morphometry-based diagnoses. Our work may inspire more tetrahedral spectral feature-based Bayesian learning research in medical image analysis.
AB - Structural and anatomical analyses of magnetic resonance imaging (MRI) data often require a reconstruction of the three-dimensional anatomy to a statistical shape model. Our prior work demonstrated the usefulness of tetrahedral spectral features for grey matter morphometry. However, most of the current methods provide a large number of descriptive shape features, but lack an unsupervised scheme to automatically extract a concise set of features with clear biological interpretations and that also carries strong statistical power. Here we introduce a new tetrahedral spectral feature-based Bayesian manifold learning framework for effective statistical analysis of grey matter morphology. We start by solving the technical issue of generating tetrahedral meshes which preserve the details of the grey matter geometry. We then derive explicit weak-form tetrahedral discretizations of the Hamiltonian operator (HO) and the Laplace-Beltrami operator (LBO). Next, the Schrödinger's equation is solved for constructing the scale-invariant wave kernel signature (SIWKS) as the shape descriptor. By solving the heat equation and utilizing the SIWKS, we design a morphometric Gaussian process (M-GP) regression framework and an active learning strategy to select landmarks as concrete shape descriptors. We evaluate the proposed system on publicly available data from the Alzheimers Disease Neuroimaging Initiative (ADNI), using subjects structural MRI covering the range from cognitively unimpaired (CU) to full blown Alzheimer's disease (AD). Our analyses suggest that the SIWKS and M-GP compare favorably with seven other baseline algorithms to obtain grey matter morphometry-based diagnoses. Our work may inspire more tetrahedral spectral feature-based Bayesian learning research in medical image analysis.
KW - Alzheimer'S disease
KW - Bayesian manifold learning
KW - Magnetic resonance imaging (MRI)
KW - Spectral shape analysis
KW - Tetrahedral mesh
UR - http://www.scopus.com/inward/record.url?scp=85108870278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108870278&partnerID=8YFLogxK
U2 - 10.1016/j.media.2021.102123
DO - 10.1016/j.media.2021.102123
M3 - Article
C2 - 34214958
AN - SCOPUS:85108870278
SN - 1361-8415
VL - 72
JO - Medical Image Analysis
JF - Medical Image Analysis
M1 - 102123
ER -